Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 Plus Nab-paclitaxel in First-line TNBC
NCT06767527Phase 3Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing AK112 Plus Nab-Paclitaxel with Placebo Plus Nab-Paclitaxel (2 arms). Primary endpoints: Progression-Free Survival assessed by IRRC and Overall Survival. Started Feb 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06767527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06767527.